Table 1.
VH and VL families of CLL IgBCRs.
| Heavy chain | Light chain | |||||||
|---|---|---|---|---|---|---|---|---|
| Patient | Sample collection time | VHDJH | VH Mutational status | VH CDR3 aa number | VH CDR3 aa sequence | (%) | VLJL | (%) |
| CLL#1 | CLL#1a (month 1) | V1-69/D3-16*01/J6*02 | U-CLL | 20 | CARDLGMITFGGDYYYYGMDVW | 60 | V3-1*01/J3*02 | 100% |
| V4-4/D2-21*01/J6*03 | U-CLL | 18 | CARVVVIVTIRGYNYYMDVW | 40 | ||||
| CLL#1b (month 5) | V1-69/D3-16*01/J6*02 | U-CLL | 20 | CARDLGMITFGGDYYYYGMDVW | 50 | |||
| V3-21*01/D3-10*01/J3*02 | M-CLL | 14 | CARDYGSGRSPPQNIW | 20 | ||||
| V3-15*07/D2-21*01/J3*02 | M-CLL | 16 | CTTAPKESRLPWEAFDIW | 10 | ||||
| V3-30*03/D5-12*01/J3*02 | M-CLL | 20 | CARGQEVDTVSKILYADTLDIW | 10 | ||||
| V4-59*01/D3-22*01/J3*02 | U-CLL | 17 | CARGLLYYDSSGYQAFDIW | 10 | ||||
| CLL#1c (month 8) | V1-69/D3-16*01/J6*02 | U-CLL | 20 | CARDLGMITFGGDYYYYGMDVW | 80 | |||
| V4-59*08/D6-13*01/J4*02 | U-CLL | 18 | CARDRWYSSSYYGGYYFDYW | 10 | ||||
| V5-10*03/D6-19*01/J4*02 | U-CLL | 12 | CARHRHSSGFGDYW | 10 | ||||
| CLL#1d (month 24) | V3-53*02/D3-09*01/J4*02 | M-CLL | 11 | CVSGYDSAKLASW | 70 | |||
| V1-69/D3-16*01/J6*02 | U-CLL | 20 | CARDLGMITFGGDYYYYGMDVW | 30 | ||||
| CLL#5 | CLL#5a (month 1) | V1-69/D7-27*01/J3*02 | U-CLL | 12 | CARSAYWGYFDIW | 75 | V1-33*01/J3*01 | 100% |
| V3-7*03/D1-7*01/J4*02 | M-CLL | 9 | CARDNWNYVYW | 25 | ||||
| CLL#5b (month 12) | V1-69/D7-27*01/J3*02 | U-CLL | 12 | CARSAYWGYFDIW | 45 | |||
| V3-49/D3-22/J3*02 | U-CLL | 20 | CTRGPPYDSSGNYLRLDAFDIW | 30 | ||||
| V4-4*02/D2-21/J6*03 | U-CLL | 18 | CARVVVIVTIRGYNYYMDVW | 30 | ||||
| V3-7*03/D1-7*01/J4*02 | M-CLL | 9 | CARDNWNYVYW | 5 | ||||
| CLL#5c (month 24) | V1-69/D7-27*01/J3*02 | U-CLL | 12 | CARSAYWGYFDIW | 35 | |||
| V3-49/D3-22/J3*02 | U-CLL | 20 | CTRGPPYDSSGNYLRLDAFDIW | 25 | ||||
| V4-4*02/D2-21/J6*03 | U-CLL | 18 | CARVVVIVTIRGYNYYMDVW | 25 | ||||
| V3-7*03/D1-7*01/J4*02 | M-CLL | 9 | CARDNWNYVYW | 15 | ||||
Blood samples were collected from patients CLL#1 and CLL#5 at the indicated time. Total RNA was extracted from purified B cells, and the IgBCR variable regions were amplified by RT-PCR, cloned in expression vectors AbVec-hIgG1 (GenBank: FJ475055.1) for the heavy chain and AbVec-hIgLambda (GenBank: FJ517647.1) for the light chain, and subject to DNA sequencing. Genetic rearrangements of the heavy (VH) and light (VL) chains were analyzed according to the International ImMunoGeneTics information system® (http://www.imgt.org). Status is defined unmutated (U-CLL) or mutated (M-CLL) based on mutational differences (<2% or >2%, respectively) compared with the germline sequence. Percentage indicates the frequency of the clone expressing the indicated VDJ rearrangement of heavy chain.